Corporate Overview - Additional Information (Detail)
|
|
|
12 Months Ended |
|
|
|
May 25, 2016
USD ($)
$ / shares
shares
|
May 15, 2015
USD ($)
$ / shares
shares
|
Dec. 31, 2016
USD ($)
$ / shares
shares
|
Dec. 31, 2015
$ / shares
shares
|
Sep. 02, 2015
Patents
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Common stock, par value | $ / shares |
|
|
$ 0.0001
|
$ 0.0001
|
|
| Sale of common stock and common stock warrants to related party | $ |
|
|
$ 2,664,900
|
|
|
| Number of securities into which the class of warrant or right converted |
|
|
53,093,902
|
0
|
|
| Finders Arrangements [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Sale of common stock and common stock warrants to related party | $ |
|
|
$ 582,500
|
|
|
| Sale of common stock and common stock warrants to related party, shares |
|
|
466,000
|
|
|
| Commission paid to agents | $ |
|
|
$ 46,600
|
|
|
| Mayne Pharma Ventures Pty LTD [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Warrants issued to purchase common stock |
|
|
28,364,236
|
|
|
| Mayne Pharma Ventures Pty LTD [Member] | Securities Purchase Agreement [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Sale of common stock and common stock warrants to related party | $ |
|
|
$ 2,788,500
|
|
|
| Sale of common stock and common stock warrants to related party, shares |
|
|
27,885,000
|
|
|
| Aggregate number of common stock and warrants issued |
|
|
27,885,000
|
|
|
| Warrants issued to purchase common stock |
|
|
27,885,000
|
|
|
| Mayne Pharma Ventures Pty LTD [Member] | Finders Arrangements [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Sale of common stock and common stock warrants to related party | $ |
|
|
$ 47,924
|
|
|
| Warrants issued to purchase common stock |
|
|
479,236
|
|
|
| Accredited Investor [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Common stock, par value | $ / shares |
$ 0.0001
|
|
|
|
|
| Exercise price of warrants | $ / shares |
0.12
|
|
|
|
|
| Shares issued, price per share | $ / shares |
$ 0.10
|
|
|
|
|
| Number of securities into which each warrant or right converted |
1
|
|
|
|
|
| Number of securities into which the class of warrant or right converted |
1
|
|
|
|
|
| Warrant expiration period |
5 years
|
|
|
|
|
| Private Placement [Member] | Accredited Investor [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Sale of common stock and common stock warrants to related party | $ |
$ 5,500,000
|
|
|
|
|
| Sale of common stock and common stock warrants to related party, shares |
55,000,000
|
|
|
|
|
| Mayne Pharma [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| License fee paid | $ |
|
|
$ 75,000
|
|
|
| Number of patents sublicensed | Patents |
|
|
|
|
2
|
| Securities Purchase Agreement [Member] | Mayne Pharma [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Share purchase agreement date |
|
|
May 18, 2015
|
|
|
| Warrant expiry date |
|
|
May 20, 2020
|
|
|
| Exercise price of warrants | $ / shares |
|
$ 0.075
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Sale of common stock and common stock warrants to related party | $ |
|
|
$ 2,712
|
|
|
| Sale of common stock and common stock warrants to related party, shares |
|
|
27,115,000
|
|
|
| Common Stock [Member] | Securities Purchase Agreement [Member] | Mayne Pharma [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Sale of common stock and common stock warrants to related party | $ |
|
$ 2,500,000
|
|
|
|
| Sale of common stock and common stock warrants to related party, shares |
|
33,333,333
|
|
|
|
| Warrants [Member] | Securities Purchase Agreement [Member] | Mayne Pharma [Member] |
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] |
|
|
|
|
|
| Common stock, par value | $ / shares |
|
$ 0.075
|
|
|
|
| Sale of common stock and common stock warrants to related party | $ |
|
$ 2,500,000
|
|
|
|
| Sale of common stock and common stock warrants to related party, shares |
|
33,333,333
|
|
|
|